Deciphera Pharmaceuticals LLC has reached the point in a biotech’s lifecycle when it transitions from scientific leadership to business leadership: on April 7, it moved its founding CEO over to the role of chief scientific officer while hiring for the top slot somebody it believes will be able to guide business development efforts on the eve of entering the clinic with its third drug candidate.
The Lawrence, Kan.-based biotech reported that Mike Taylor has taken over as president and CEO from founder Dan Flynn, who now will serve as chief scientific officer. The company also...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?